semaglutide

Stories 1 - 20 |  Next >>

Taking GLP-1 Drugs and Feeling 'Meh'? You're Not Alone

Patients report emotional 'flattening' (aka 'Ozempic personality') while taking popular weight-loss drugs

(Newser) - For some people on blockbuster weight-loss drugs, the number on the scale isn't the only thing dropping—in some cases, their sense of joy is, too. Patients on GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are reporting a "flattening" of emotions: Sunsets, hobbies, even sex can start...

Ozempic Goes Generic —But Not in the US

Lower-cost semaglutide generics expected to widen access across much of the globe

(Newser) - A drug that helped turn Novo Nordisk into Europe's most valuable company is about to lose its monopoly grip across much of the globe. Patent protections on semaglutide—sold as Ozempic for diabetes and Wegovy for weight loss—expire Saturday in several of the world's most populous countries,...

Wegovy Is Going High-Dose
Coming Soon: 'Wegovy HD'
Mar 20, 2026 6:13 AM CDT

Coming Soon: 'Wegovy HD'

FDA approves a new high-dose version of the obesity drug

(Newser) - Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users lose more weight and keep it off. The US Food and Drug Administration approved a 7.2-milligram dose of Danish drugmaker Novo Nordisk's semaglutide. Previously, the highest approved dose of...

The Novo Nordisk-Hims & Hers Feud Is Over

Telehealth firm to sell Ozempic, Wegovy and drop compounded rivals

(Newser) - Novo Nordisk just swapped a courtroom fight for a sales deal with Hims & Hers—and investors loved it, reports CNBC . The Danish drugmaker has dropped its patent-infringement case against the telehealth company after Hims agreed to sell Novo's branded weight-loss drugs Ozempic and Wegovy through its platform, at...

Many Ozempic Users Can Maintain Weight With Fewer Doses

Small pilot suggests lower, less-frequent doses may still maintain benefits of obesity-busting drug

(Newser) - People on weight-loss drugs like Ozempic may not need to jab themselves nearly as often as they think, a small new study suggests. Researchers at Scripps Health followed 30 patients on GLP-1 medications—including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound)—who'd hit a weight plateau and then shifted to less...

RFK Jr.'s FDA Plans a 180 on Controversial Peptides

Agency will nix Biden-era limits on more than a dozen peptides from compounding pharmacies

(Newser) - Robert F. Kennedy Jr. is promising a big shift in the booming, barely regulated world of peptides. On Joe Rogan's Friday podcast , the Health and Human Services secretary said the Food and Drug Administration is poised to lift restrictions on roughly 14 peptides that were effectively banned from production...

Child Obesity Hits Record High, as Adult Rates Level Off

CDC data show 1 in 5 youths is now considered obese, up from 1 in 20 in the early '70s

(Newser) - American adults may finally be hitting a plateau on obesity. Kids, however, are not. Two new CDC reports based on decades of federal health survey data find, among other things, that 40.3% of US adults ages 20 and older were obese between August 2021 and August 2023, slightly below...

Novo Nordisk to Slash US List Prices for Ozempic, Wegovy

Price reductions of up to 50% starting in 2027 aim to ease patient costs, challenge Eli Lilly

(Newser) - Novo Nordisk is planning a major markdown on two of the hottest drugs in medicine, though not for another year. The Danish drugmaker says it will cut the US list prices of its weight-loss shot Wegovy and diabetes drug Ozempic by up to 50%, bringing both to $675 a month...

Novo Nordisk's New Obesity Drug Fails a Big Test

CagriSema does not outperform Zepbound in trial, and Novo's stock sinks

(Newser) - Novo Nordisk just learned its latest much-hyped obesity drug may not actually live up to the hype. Shares of the Danish pharma giant plunged 16% Monday after it reported that its experimental drug, CagriSema, did not match the weight loss achieved by Eli Lilly's rival drug in a direct...

Hims & Hers Drops Plans for Copycat Wegovy Drug

Telehealth company faced legal threats over plans to undercut bigger rival's price

(Newser) - Hims & Hers won't be rolling out a knockoff version of the new Wegovy weight-loss pill after all. The telehealth company dropped its plans Saturday after the FDA threatened to limit access to the active ingredients for copycat GLP-1 drugs, reports the AP . The company also faced legal threats...

Don't Rely Too Much on Those 'GLP-1 Friendly' Labels

Nutrition experts say labels aren't regulated by FDA, may be misleading for GLP-1 users

(Newser) - Meals and snacks with "GLP-1 Friendly" labels on the packaging are becoming more common in US supermarkets as a growing number of Americans try obesity drugs like Wegovy, Ozempic, Zepbound, and Mounjaro to lose weight. But the labels aren't regulated by the FDA, unlike the popular medications themselves,...

Wegovy Now Available in Pill Version

Novo Nordisk rolls out new GLP-1 weight-loss option

(Newser) - A new stage in the boom of weight loss drugs began on Monday: Novo Nordisk rolled out a pill version of Wegovy nationwide, reports the Washington Post . The company is betting that a pill will expand the GLP-1 market to those leery of shots. Doctors can now prescribe the once-daily...

Semaglutide Fails to Slow Alzheimer's in Major Trials

Major trials show no benefit for early Alzheimer's patients

(Newser) - A closely anticipated trial has concluded with disappointing results for Novo Nordisk's blockbuster drug semaglutide, the active ingredient in Ozempic and Wegovy. The company announced on Monday that two large studies found the drug did not slow cognitive decline or improve daily functioning in people with early Alzheimer's...

Patients With Colon Cancer May See Extra GLP-1 Benefits

Those on weight loss drugs like Ozempic, Wegovy see lower death rates than those not taking them

(Newser) - Medications like Wegovy and Ozempic, known for managing diabetes and promoting weight loss, may also be linked to significantly lower death rates in colon cancer patients, according to a new study cited by the Independent . Researchers at UC San Diego reviewed medical records for more than 6,800 colon cancer...

Costco Is Hawking Ozempic, Wegovy at Pharmacies

Members would pay $499 a month without insurance

(Newser) - Costco is getting in on the surging popularity of weight-loss drugs. The warehouse chain is bringing the blockbuster drugs Ozempic and Wegovy to its pharmacies in the US, reports the New York Times . Members with a prescription can purchase a four-week supply of either drug for $499—roughly half...

Wegovy Pill Matches Shot for Weight Loss in Clinical Trial

Daily pill delivered similar results to injectable version in Novo Nordisk trial

(Newser) - Novo Nordisk's pill version of Wegovy could be just as effective as the injectable shot, according to new clinical trial data released by the company. In the study, overweight or obese adults took the daily oral medication as prescribed lost an average of 16.6% of their body...

GLP-1 Drugs Now Considered Essential Medicines

Semaglutide, tirzepatide join WHO list in hope of boosting access in low-income countries

(Newser) - For the first time, the World Health Organization has named popular GLP-1 weight loss drugs as essential medicines, a move set to reshape access to the treatments in countries with limited healthcare resources. The move means semaglutide, the active ingredient in Novo Nordisk's Ozempic, and tirzepatide, the active...

Telehealth, Pharma Giants Split in Acrimonious Fashion

Novo Nordisk cuts ties with Hims, and the latter firm's shares plunge

(Newser) - Shares of Hims & Hers plunged over 30% after Wegovy maker Novo Nordisk abruptly ended their partnership on Monday, accusing the telehealth company of selling unauthorized versions of its popular weight-loss drug. As the Wall Street Journal reports, the split exposes growing tensions between pharmaceutical giants and telehealth firms...

Think Weight-Loss Meds Beat Surgery? Maybe Reconsider

Bariatric surgery still outperforms injections for long-term weight loss, researchers find

(Newser) - A new study suggests that popular weight-loss injections like Wegovy and Mounjaro don't deliver the same dramatic results in everyday use as they do in clinical trials. The drugs, which contain semaglutide and tirzepatide, have been hailed for helping some trial participants lose up to 20% of their...

The GLP-1 Drug Landscape Changes on Thursday

Off-brand Ozempic products will no longer be permitted to be sold

(Newser) - The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer be permitted to be sold—creating a possible problem for the Americans who've come to rely on the generally cheaper option. The FDA in February announced that the shortage of the active...

Stories 1 - 20 |  Next >>
Most Read on Newser